Evolution of the Average Target: Xylem Inc.

Evolution of the Average Target - Xylem Inc.

Evolution of the Target Price: Xylem Inc.

Evolution of the Target Price - Xylem Inc.

Changes in Analyst Recommendations: Xylem Inc.

fadfe2d99853.6yIdYG-QdJ4h-ftOIFmCWSv20lwuH_5xhmb1YsMwg_U.o01HECr1H-cYwL16RBPWIGKekQ9bKM0L5VCEG7Rm4JCvVykhF8AFrHOTvg~3c95cf273515c332f6605228fcd2fcdf
05/11 Argus Research Downgrades Xylem to Hold From Buy MT
02/11 Rothschild & Co Redburn Cuts Price Target on Xylem to $129 From $165 MT
02/11 Analyst recommendations: Adobe, Caterpillar, Fair Isaac, Regeneron Pharmaceuticals… Zonebourse
30/10 UBS Adjusts Xylem Price Target to $99 From $112, Maintains Neutral Rating MT
30/10 Not All AI Billions Are Equal Zonebourse
30/10 Barclays Downgrades Xylem to Equalweight From Overweight, Price Target is $104 MT
29/10 Analyst recommendations: Boston Scientific, Hilton, Kla Corporation, Fortinet, Microsoft… Zonebourse
29/10 Oppenheimer Adjusts Price Target on Xylem to $135 From $150, Maintains Outperform Rating MT
29/10 RBC Cuts Price Target on Xylem to $125 From $135, Keeps Outperform Rating MT
28/10 Citigroup Adjusts Price Target on Xylem to $130 From $148 MT
28/10 Analyst recommendations: Boeing, Qiagen, Spotify, Applovin, Fedex… Zonebourse
28/10 BNP Paribas Adjusts Price Target on Xylem to $135 From $145 MT
28/10 Goldman Sachs Adjusts Price Target on Xylem to $138 From $160 MT
28/10 JPMorgan Downgrades Xylem to Underweight From Neutral, $90 Price Target MT
19/10 JPMorgan Adjusts Price Target on Xylem to $118 From $137 MT
15/10 Mizuho Adjusts Price Target on Xylem to $110 From $130 MT
15/10 Xylem's YTD Stock Performance Reflects Fears Around Sustained Top-Line Pressure, Oppenheimer Says MT
14/10 Oppenheimer Adjusts Xylem Price Target to $150 From $158, Maintains Outperform Rating MT
14/10 RBC Capital Adjusts Xylem Price Target to $135 From $164, Maintains Outperform Rating MT
12/10 Citigroup Adjusts Price Target on Xylem to $148 From $172 MT
06/10 UBS Adjusts Price Target on Xylem to $112 From $138, Keeps Neutral Rating MT
01/10 BNP Paribas Adjusts Price Target on Xylem to $145 From $160, Maintains Outperform Rating MT
24/08 Jefferies Adjusts Price Target on Xylem to $150 From $145 MT
13/08 UBS Adjusts Price Target on Xylem to $138 From $135, Keeps Neutral Rating MT
12/08 Argus Adjusts Price Target on Xylem to $140 From $125, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+32.53%
+23.59%
+19.11%
-0.35%
-5.89%
+47.54%
+14.74%
+16.79%
+35.16%
+17.23%
Average +20.04%
Weighted average by Cap. +18.19%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
94.65USD
Average target price
125.44USD
Spread / Average Target
+32.53%
High Price Target
180.00USD
Spread / Highest target
+90.17%
Low Price Target
90.00USD
Spread / Lowest Target
-4.91%

Analyst Consensus Detail

Analyst consensus - Xylem Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Xylem Inc.
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Xylem Inc.
  1. Stock Market
  2. Stocks
  3. XYL Stock
  4. Consensus Xylem Inc.